YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Aclaris Therapeutics (ACRS) shares ended the last trading session 6% higher at $5.64. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8% loss ove…
Aclaris Therapeutics, Inc. WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases…
[Heart Health Concept] Eoneren/E+ via Getty Images Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price velocit…
(RTTNews) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports. Bioventus Inc. (BVS) Bioventus is a medical device company that focuses on technology for pain management an…
(RTTNews) - The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies. Xencor Inc. (XNCR) Xencor is a clini…
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Stocks trading below $10 often attract retail investors looking for high-growth opportunities at relatively low entry prices. However, many of these low-priced equities can…
Aclaris Therapeutics (ACRS) shares ended the last trading session 5.4% higher at $5.29. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.7% gai…
Key Points Interested in Ur Energy Inc? Here are five stocks we like better. These three penny stocks generate real revenue, separating them from many speculative story stocks. Ur-Energy, Grab Holdings, and Aclaris Therapeutics each have c…
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the top penny stocks to buy in investors’ stock portfolio. On May 8, Stifel reiterated a Hold rating on Aclaris Therapeutics Inc. (NASDAQ:ACRS) and increased the price target to $4 from $3.…
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thu…
- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Estimated Half-Life of…
(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) is preparing to release new clinical results for two of its lead immuno-inflammatory drug candidates, marking an important update in the company's biologic and oral inhibitor pipeline. The comp…
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an e…
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 202…
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.66 per share a year ago. These figures are adjusted for non-recurring item…
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.2 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring…
As February 2026 begins, the U.S. stock market has seen a robust start, with major indexes like the Dow Jones Industrial Average and S&P 500 posting significant gains. This positive momentum reflects broader economic optimism and renewed i…
On February 2, BML Capital Management, LLC disclosed a new position in CarMax(NYSE:KMX), acquiring 155,000 shares in an estimated $5.99 million trade based on quarterly average pricing. What happened According to an SEC filing dated Februa…
On February 2, BML Capital Management disclosed in a Securities and Exchange Commission filing that it sold out of Alumis(NASDAQ:ALMS), liquidating 1,210,415 shares in an estimated $4.83 million trade. What happened According to a Securiti…
WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it ha…
(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) on Tuesday reported positive interim results from a Phase 1a single-ascending dose (SAD) and multiple-ascending dose (MAD) trial of ATI-052. The company said ATI-052 was well tolerated and demo…
Aclaris Therapeutics, Inc. WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases,…
WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has bee…
WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Dr. N…
* Aclaris Therapeutics press release [https://seekingalpha.com/pr/20296245-aclaris-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate] (ACRS [https://seekingalpha.com/symbol/ACRS]): Q3 GAAP EPS of -$0.12 beats…
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring…
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the C…
WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the…
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is among the best fundamentally strong penny stocks to buy right now. According to the recent Form 13F filing with the SEC, Acadian Asset Management LLC expanded its holdings in Aclaris Therapeutics…
Xencor (XNCR) shares soared 7.3% in the last trading session to close at $9.25. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 13.6% gain over the past four we…
- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical…
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the C…
Aclaris Therapeutics (ACRS) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's ear…
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT RCON [https://www.chartmill.com/stock/quote/RCON/profile] 23.45…
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved…
- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa…